Rezum water vapor therapy for patients with mild, moderate, or severe lower urinary tract symptoms: A retrospective study in a multiethnic population

Babar, Mustufa; Loloi, Justin; Tang, Kevin; Singh, Sandeep; Ines, Matthew; Patel, Rutul D.; Iqbal, Nazifa; Ciatto, Michael

doi:10.1002/pros.24508

Cited by 2 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A higher proportion of patients in the > 80 cc cohort had a past medical history of urinary retention (25%) compared to the < 30 cc (5.7%, P ¼ .04) and 30 to 80 cc (4.1%, P < .001) cohorts. The < 30 cc cohort had significantly higher baseline IPSS (median 21 [IQR 15 -28]) and QoL (5 [4-6]) compared to the 30 to 80 cc (IPSS 17 [10][11][12][13][14][15][16][17][18][19][20][21][22][23] Regarding IIEF measures, at 48 months there was slight worsening of orgasmic function in the < 30 cc cohort (À50%, P ¼ .04) but an improvement in the 30 to 80 cc cohort (25%, P ¼ .004). At 48 months, erectile function improved in the 30 to 80 cc cohort (15.4%, P ¼ .006) with insignificant changes in the < 30 cc and > 80 cc cohorts.…”

Section: Baseline Demographicsmentioning

confidence: 99%

“…16 While current literature is favorable, long-term real-world data remain limited. [17][18][19][20][21] Additionally, WVTT is indicated only for men with a PV between 30 cc and 80 cc, as studied in its randomized control trial. 12,22 This excludes men with larger PVs (who may bear greater morbidity) and with smaller PVs (who may also benefit from reduction of excess tissue).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Long-Term Water Vapor Thermal Therapy Outcomes Across a Broad Range of Prostate Volumes

Hawks-Ladds,

Tawfik,

Babar

et al. 2024

Urology Practice

View full text Add to dashboard Cite

Section: Baseline Demographicsmentioning

confidence: 99%

mentioning

confidence: 99%

Long-Term Water Vapor Thermal Therapy Outcomes Across a Broad Range of Prostate Volumes

Hawks-Ladds,

Tawfik,

Babar

et al. 2024

Urology Practice

View full text Add to dashboard Cite

Four years of real-world sexual function outcomes after Rezum therapy in men with and without baseline erectile dysfunction

Hawks-Ladds,

Cook,

Babar

et al. 2024

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Background Rezum alleviates lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH) while preserving sexual function, but long-term sexual function outcomes are lacking in patients with baseline erectile dysfunction (ED). Aim The study sought to analyze 4 years of real-world sexual function outcomes of Rezum using the International Index of Erectile Function (IIEF) questionnaire, stratified by baseline ED status. Methods Participants included multiethnic Rezum-treated patients from a single outpatient office. IIEF domains and BPH medication usage were compared at baseline and 6, 12, and 48 months using t tests, Mann-Whitney U tests, chi-square tests, and Wilcoxon signed rank tests. Outcomes Primary outcomes over 4 years included the IIEF functional domains (erectile function [EF], orgasmic function [OF], sexual desire [SD], intercourse satisfaction [IS], overall satisfaction [OS]) and BPH medication usage. Results A total of 91 patients were included: 40 (44%) in the ED cohort and 51 (56%) in the no ED cohort. History of diabetes was more prevalent in the ED cohort (35% vs 15.7%; P = .048). Baseline scores in the EF, OF, IS, and OS domains were lower in the ED cohort. Compared with baseline, there were no significant changes in any IIEF domains in either cohort at 6 months. At 12 months, the ED cohort had significant percent decreases in OF (−25%; P = .02), SD (−22.2%; P = .04), and OS (−33.3%; P = .004); the no ED cohort had a significant percent increase in EF (5%; P = .04). At 48 months, the no ED cohort had no significant changes in any IIEF domains, while the ED cohort had significant percent increases in EF (30%; P = .01), SD (22.5%; P = .02), IS (20%; P = .01), and OS (58.3%; P = .008). Both cohorts significantly discontinued BPH medications at all follow-ups. At 48 months, there were no cases of de novo ED in the no ED cohort. Clinical Implications As modern BPH therapies continue to demonstrate efficacy in alleviating lower urinary tract symptoms, the preservation or improvement of sexual function emerges as an increasingly important consideration for patients, with our study suggesting Rezum as a compelling option. Strengths and Limitations Our study has the strength of long-term Rezum outcomes in an ethnically diverse patient population, stratified by the presence of baseline ED, but is limited by retrospective design, single-center nature, and small sample sizes at long-term follow-ups. Conclusion Rezum preserved long-term sexual function in patients without baseline ED and improved sexual function in those with baseline ED; however, individuals with ED may experience temporary decreases in sexual function at 12 months.

show abstract

Rezum water vapor therapy for patients with mild, moderate, or severe lower urinary tract symptoms: A retrospective study in a multiethnic population

Cited by 2 publications

References 30 publications

Long-Term Water Vapor Thermal Therapy Outcomes Across a Broad Range of Prostate Volumes

Long-Term Water Vapor Thermal Therapy Outcomes Across a Broad Range of Prostate Volumes

Four years of real-world sexual function outcomes after Rezum therapy in men with and without baseline erectile dysfunction

Contact Info

Product

Resources

About